Tarsus Pharmaceuticals (TARS) just put commercial leadership in sharper focus by naming Neera Clase as permanent Chief Commercial Officer ahead of its upcoming earnings update and the ongoing commercialization of XDEMVY and late stage eye care pipeline assets.
The leadership update lands after a choppy stretch for Tarsus Pharmaceuticals. The stock has a 90 day share price return of 25.68% and a 1 day move of 2.98%. However, the 30 day share price return is down 5.61% and the year to date share price return is down 8.13%. The 3 year total shareholder return is about 4.6x and the 5 year total shareholder return sits at about 2.7x, suggesting long term holders have already seen substantial value creation even as recent momentum has cooled.
Scan how other eye care and biotech players stack up by revenue, pipeline and balance sheet strength alongside Tarsus Pharmaceuticals with the hand picked 18 high quality undiscovered gems.
Is the recent climb in Tarsus Pharmaceuticals a clear reflection of progress around XDEMVY and the pipeline, or mostly a sentiment shift ahead of earnings and leadership change, and how might that tension appear in the valuation next?
Most Popular Narrative: 25% Undervalued
Against a last close of $74.20, the most widely followed narrative anchors Tarsus Pharmaceuticals at a fair value of $99.50. This is a sizeable gap that puts a lot of weight on how XDEMVY and the broader lotilaner platform scale from here.
Accelerated patient and physician adoption of XDEMVY, driven by a robust direct-to-consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top-line revenue growth.
Broad and expanding market access, including 90% coverage among commercial, Medicare, and Medicaid plans, removes reimbursement as a major barrier and supports higher net sales realization and margin preservation over time.
See why 14 investors see Tarsus Pharmaceuticals as 25% undervalued.
Result: Fair Value of $99.50 (UNDERVALUED)
Still, the whole story for Tarsus Pharmaceuticals hinges on XDEMVY carrying a heavy load, so any slowdown in uptake or payer pressure on pricing could quickly challenge that 25% undervalued narrative.
Find out about the key risks to this Tarsus Pharmaceuticals narrative.
Another View: What Multiples Say About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals screens very differently once you look at simple sales-based pricing. The stock trades on a P/S of 5.4x, which is richer than the US Pharmaceuticals average of 4.5x, yet well below peers at 12.3x and below the fair ratio of 8.4x that the market could move toward. That mix of premium to the sector but discount to closer comparables points to meaningful valuation risk if execution slips, but also room for re-rating if the XDEMVY story holds up. The key question is which side you think the market is pricing in today.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages in the recent moves around Tarsus Pharmaceuticals and XDEMVY. If you want a fuller picture, consider both perspectives in the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Tarsus Pharmaceuticals?
If Tarsus Pharmaceuticals has you thinking about what else might be worth your attention, do not leave potential opportunities on the table. Use a few focused tools to spot fresh ideas that fit your style and risk limits.
- Target potential upside with a curated list of companies that screen as 30 high quality undervalued stocks.
- Prioritize resilience and sleep better at night by homing in on a 30 resilient stocks with low risk scores.
- Protect your cash and keep options open by focusing on a list of solid balance sheet and fundamentals (23 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com